XKRX
052020
Market cap215mUSD
Aug 16, Last price
6,270.00KRW
Name
STCube Inc
Chart & performance
P/E
—
P/S
25.66
EPS
—
Div yield, %
—
Shrs. gr., 5y
10.00%
Rev. gr., 5y
-8.26%
Revenues
11.30b
+93.88%
Net income
-21.44b
L-12.50%
CFO
-23.90b
L-3.40%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Stcube Inc operates as a biopharmaceutical enterprise, specializing in the development of medical treatments. Their work specifically addresses the novel strategies cancer employs to bypass the body's immune defenses, with a particular focus on the Korean market.
Key people
Hoon Choi
Vice President, Director
Seok Ho Jeon
Internal Auditor
Dong Pyo Shin
Internal Auditor
Sun Hyeok Uhm
Internal Auditor · since 2013
Martin Graham
Director · since 2013
Hyeon Jin Jung
Chief Executive Officer, Director · since 2013
Tae Wun Min
Director · since 2012
Byeong Su Park
Director · since 2008
Ji Won Park
Director · since 2012
Jun Yong Park
Vice President, Director
Seon Jong Sung
Director · since 2010
Hun Lee
Non-Executive Independent Director · since 2022
Dong Won Lee
Non-Executive Independent Director · since 2022
Geun Dong Lee
Non-Executive Independent Director · since 2013
Yeong Sik Seo
Non-Executive Independent Director · since 2007
Chang Seon Shin
Non-Executive Independent Director · since 2007
Jiyoung Yoo
Non-Executive Independent Director · since 2013
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||